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Introduction
The genetic engineering of tumor cells has contributed considerably to the development of new (immuno) therapeutic strategies of cancer. Tumor cells have been engineered to produce a whole array of different cytokines or to express at the cell surface co-stimulatory molecules in order to enhance the immunogenicity of poorly or nonimmunogenic tumors and thereby produce an effective antitumor vaccine. [1] [2] [3] Live genetically modified tumor cell vaccines appear to be more effective than irradiated tumor cell vaccines. 4, 5 The higher immunogenicity of live genetically modified tumor cell vaccines may result from a prolonged production of cytokines or from initial tumor formation that regresses as a result of a local non-specific reaction. 5, 6 The potential dangers of using live genetically modified tumor cell vaccines are their sometimes maintained intrinsic tumorigenic properties and the absence of an effective local antitumor reac-tion that eliminates all tumor cells. Introduction of a suicide gene into live tumor cell vaccines, permitting their selective in vivo elimination with prodrug treatment, may overcome these problems.
The two best studied and most used suicide genes are the herpes simplex virus thymidine kinase (HSVtk) gene and the cytosine deaminase (CD) gene. The prodrug ganciclovir is a non-toxic nucleoside analog that is phosphorylated by HSVtk into a monophosphorylated form, which is then converted into triphosphate forms which are incorporated into elongating DNA during cell division causing death of dividing cells. 7 The high sensitivity of the HSVtk and the very low sensitivity of mammalian tk for ganciclovir allows the selective kill of HSVtk-expressing cells among a population of normal mammalian cells. Cytosine deaminase catalyzes the deamination of the non-toxic prodrug 5-fluorocytosine (5-FC) into the highly toxic 5-fluorouracil. 8 CD is not present in mammalian cells. Expression of CD in mammalian cells confers lethal sensitivity to 5-FC. 9 It has been demonstrated that the introduction of a suicide gene into tumor cells by itself can be sufficient to enhance their immunogenicity and that the in vivo elimination of suicide gene-expressing tumor cells with prodrug treatment can induce protective immunity against wild-type tumors. [10] [11] [12] It has been suggested that the localized in vivo killing of suicide gene-transduced tumor cells may lead to the release of a massive load of tumor cell debris and efficient uptake and presentation of tumor-associated antigens by antigen presenting cells, in a manner different from that which occurs when lethally irradiated tumor cells desintegrate in vivo. 6, 10 In several solid tumor models, it has been shown that prodrug treatment can result in complete tumor regressions even when only a fraction of the tumor cells express the suicide gene, a phenomenon termed the 'bystander effect'. [13] [14] [15] The bystander effect of HSVtk gene transduced cells results from metabolic cooperation through gap-junctions or from phagocytosis by wild-type tumor cells of apoptotic vesicles generated from the dying HSVtk transduced tumor cells. [15] [16] [17] The sensitivity to bystander cell killing differs among cell lines. 18 In general, adherent cell types are sensitive to bystander cell lysis by HSVtk-expressing cells exposed to ganciclovir, whereas cell lines growing in suspension and also primary T lymphocytes are resistant to bystander cell lysis in the HSVtk/ganciclovir system. 19, 20 In this study, we analyzed the efficacy and safety of the in vivo elimination of HSVtk-expressing, bystander cell killing-insensitive leukemic cells with ganciclovir treatment. The in vivo occurrence of HSVtk loss variants is described.
Results
In vitro characterization of HSVtk-expressing rat leukemic cells Rat leukemic LT12 cells were transfected with the pLTk+Neo⌬Mo vector containing the HSVtk gene and the Neo R gene separated by a short intercistronic sequence in a bicistronic unit. Transfected cells, designated LT12/Tk+N, were selected and cloned in medium containing 400 g/ml G418. Twenty G418-resistant clones were obtained. The clones were tested for their increased sensitivity to ganciclovir using in vitro proliferation inhibition assays. The 20 transfected LT12 clones were approximately 1000-to 10 000-fold more sensitive to ganciclovir than parental LT12 cells (data not shown). The ID 50 value, the concentration of ganciclovir that inhibits proliferation by 50%, of parental LT12 cells was around 10 −4 m (Figure 1 ( Figure 1 ), indicating that the HSVtk gene is indeed stably expressed in the absence of a G418 selection pressure.
The in vitro growth of LT12 and LT12/Tk+N-2 cells was similar in normal culture medium. Also cell morphology appeared unchanged in the LT12/Tk+N-2 cells compared with parental LT12 cells.
Sensitivity of LT12 cells to bystander cell lysis in vitro
The sensitivity of LT12 cells to bystander cell lysis by LT12/Tk+N-2 cells exposed to ganciclovir was examined in in vitro co-culturing experiments. LT12/Tk+N-2 cells and LT12 cells, mixed at various ratios, were cultured in the presence of 10 −6 m ganciclovir. This concentration of ganciclovir did not effect the proliferation of LT12 cells but completely abrogated the proliferation of LT12/Tk+N-2 cells (data not shown). The proliferation of the mixed cell populations was not below the calculated proliferation in the absence of bystander cell lysis at any of the ratios tested (data not shown). The calculated proliferation is the sum of the proliferation of the relevant numbers of LT12 and LT12/Tk+N-2 cells cultured separately in the presence of ganciclovir.
Intercellular transfer of the toxic phosphorylated nucleoside analogs, that originate from the phosphorylation of ganciclovir by HSVtk, requires cell-cell contact and presumably takes place through gap-junctions. 15, 16 In contrast, the toxic metabolite 5-fluorouracil, generated from 5-fluorocytosine by cytosine deaminase, can freely diffuse from one cell to another.
14 Therefore, we also analyzed the sensitivity of LT12 cells to bystander cell lysis by CD gene transfected LT12 cells (LT12/CD-1), exposed to 5-fluorocytosine in in vitro co-culturing experiments. Various mixtures of LT12 and LT12/CD-1 cells were cultured in the presence of 1.5 mm 5-FC, which abrogated LT12/CD-1 cell proliferation but had no effect on the proliferation of LT12 cells (data not shown). The proliferation of the mixed cell populations was completely abrogated at LT12 to LT12/CD-1 cell ratios below 3:1 (data not shown). Even at a ratio of 10:1, the proliferation was markedly below the calculated theoretical proliferation in the absence of bystander cell lysis. In conclusion, LT12 cells were resistant to bystander cell lysis by LT12/Tk+N-2 cells exposed to ganciclovir but were sensitive to bystander cell lysis by LT12/CD-1 cells exposed to 5-FC. taken the day before the start of the ganciclovir treatment and grown in vitro in the presence and absence of G418, showed the same high sensitivity to ganciclovir in in vitro proliferation inhibition assays as the originally injected LT12/Tk+N-2 cells (Figure 3 ). However late recurrences of s.c. tumors were observed in two of the three ganciclovir-treated rats. The recurrent tumors consisted of a few nodules, suggesting that they arose from only a few cells. Recurrent tumors were no longer sensitive to ganciclovir treatment, indicating that they lost the functional expression of the HSVtk gene. Therefore, needle aspirates were taken from different nodules of these two recurrent tumors after the second cycle of ganciclovir treatment for in vitro analysis. In contrast to the cells in the aspirates from the primary tumors, the cells in the five aspirates of the two recurrent tumors did not grow in G418-containing medium and showed in vitro a sensitivity to ganciclovir that was comparable to parental LT12 cells (Figure 3 ), despite the presence of both the HSVtk and the Neo R genes as detected by PCR. To obtain an insight in the frequency with which HSVTk-loss variants occurred when LT12/Tk+N-2 cells were exposed to ganciclovir, various numbers of LT12/Tk+N-2 cells were seeded in soft agar in the presence or absence of ganciclovir ( Table 1) . Seeding of 200 and 400 LT12/Tk+N-2 cells in soft agar in the absence of ganciclovir resulted in 113 and 248 colonies, respectively, demonstrating that the plating efficiency of the cells was around 60%. In the presence of 10 −6 m ganciclovir, on average one in every 2 × 10 4 LT12/Tk+N-2 cells yielded a ganciclovir-resistant colony (Table 1) . Thus, after correction for the 60% plating efficiency, the frequency of occurrence of HSVtk-loss variants in the in vitro soft agar cloning assay was found to be approximately 1 in 10 4 cells.
In vivo elimination of

Resistance of LT12 cells to bystander cell lysis in vivo
The occasional occurrence of late tumors that were formed by HSVtk-loss variants, after ganciclovir treatment of rats that were s.c. injected with LT12/Tk+N-2 cells, indicates that HSVtk-loss variants were resistant to bystander cell killing in vivo. To confirm the in vivo resistance of LT12 cells to bystander cell lysis, 5 × 10 Table 2 , groups 6-8). Rats were treated with ganciclovir from days 7 to 11. Subcutaneous tumors developed at the same time and grew at a comparable rate in rats that received mixtures of LT12/Tk+N-2 and LT12 cells and rats that received identical numbers of LT12 cells only (Figure 4 ). To analyze whether tumors arising in rats that received mixtures of LT12/Tk+N-2 and LT12 cells, after ganciclovir treatment consisted of LT12 cells only, needle aspirates were taken from tumors from each rat that received a mixture with a ratio of LT12 to LT12/Tk+N-2 cells of one to 10 (Table 2, group 3). Cells from the six aspirates which did not grow in G418-containing medium, were negative in PCR analysis of genomic DNA with HSVtk Neo R primers (sensitivity of the PCRs was 10 −2 ). Moreover, cells from the six aspirates showed an in vitro sensitivity to ganciclovir that was comparable to LT12 cells (data not shown). These results suggest that these tumors indeed Table 2 , groups 9-11). Non-vaccinated control rats received only the tumorigenic doses of LT12 cells (Table  2 , groups 6-8). Vaccinated and control rats were treated with ganciclovir from day 7 until day 11. Ganciclovir treatment effectively prevented outgrowth of s.c. LT12/Tk+N-2 tumors in the right flank in 22 out of 24 vaccinated rats. All vaccinated, ganciclovir-treated rats (groups 9-11) and the non-vaccinated, ganciclovir-treated control rats (groups 6-8) developed LT12 tumors ( Table  2 ). The in vivo elimination of LT12/Tk+N-2 cells with ganciclovir did not induce growth retardation of the contralateral LT12 tumors in the vaccinated rats as compared with LT12 tumors in the control rats ( Figure 4) . Growth of LT12 tumors in ganciclovir-treated rats ( Table 2 , group 7) was slightly reduced compared with the growth of LT12 tumors in non-treated rats ( Table 2 , group 12) (data not shown). Two out of a total of 24 vaccinated, ganciclovir-treated rats developed a late s.c. LT12/Tk+N-2 tumor in the right flank, despite early ganciclovir treatment (one
Figure 4 Effect of ganciclovir-induced elimination of s.c. injected LT12/Tk+N-2 cells on the growth of contralateral-or co-injected LT12 tumors. BN rats were injected s.c. in the right flank with 5 × 10 5 LT12/Tk+N-2 cells at day 0. Various numbers of parental LT12 cells were either co-injected in the right flank (᭹) or injected in the contralateral flank (᭺) (see also Table 2). Control BN rats were injected s.c. in the right flank with various numbers of LT12 cells only (ᮀ). Rats were treated with ganciclovir from days 7 to 11. Tumor size was measured at the site where parental LT12 cells were injected. The mean tumor size of the six rats of each group and s.e.m. are indicated.
in group 2 and one in group 9, Table 2 ).
In vitro analysis of cells from needle aspirates from these two tumors demonstrated that both late s.c. tumors consisted of HSVtk loss variants that still contained the HSVtk gene but lacked functional HSVtk activity (data not shown).
To analyze further the immunogenic properties of in vivo elimination of s.c. LT12/Tk+N-2 cells by ganciclovir treatment, vaccinated ganciclovir-treated BN rats were challenged with 10 4 parental LT12 cells i.v., 3 days after termination of ganciclovir treatment. In addition, vaccinated ganciclovir-treated rats were also challenged with 10 5 LT12/Tk+N-2 cells i.v., to determine whether an immune response was elicited against the HSVtk gene product. The challenging cell dose of LT12/Tk+N-2 cells was 10-fold higher than of LT12 cells because of the 10-fold reduced leukemogenicity of LT12/Tk+N-2 cells. Control rats were challenged with the same number of LT12 or LT12/Tk+N-2 cells without prior vaccination. The survival times of the vaccinated, ganciclovir-treated rats and the control rats challenged with LT12 cells were similar ( Figure 5 ). Also the survival times of the vaccinated, ganciclovir-treated rats and the control rats challenged with LT12/Tk+N-2 cells were similar ( Figure 5 ). These results indicate that prophylactic in vivo elimination of LT12/Tk+N-2 cells did not elicit an anti-leukemic or anti-HSVtk immune response.
Discussion
In vivo elimination of live suicide gene expressing tumor cell vaccines with prodrug treatment is a promising therapeutic strategy of cancer. The safety of this approach depends on the capacity to completely eradicate all live tumor cells in the vaccine by prodrug treatment, the 'bystander effect', an effective local anti-tumor response or a combination thereof. In this study, we show that the rat AML cell line LT12, like primary T cells and EBVtransformed B cells, 19, 20 is resistant to bystander cell lysis in vitro and in vivo in the HSVtk/ganciclovir system. Our results confirm that cells which are not sensitive to 
cells (̅). Non-vaccinated control BN rats were challenged with either 10 4 parental LT12 cells () or 10 5 LT12/Tk+N-2 cells (̆). Each group consisted of six rats.
bystander cell lysis in the HSVtk/ganciclovir system can be sensitive to bystander cell lysis in the CD/5-FC system. 20, 21 The different sensitivities to bystander cell lysis in different suicide gene/prodrug systems relate to the differences in the mode of intercellular transport of their toxic metabolites. The toxic metabolite of ganciclovir cannot freely diffuse over the cell membrane. Intercellular transfer of phosphorylated ganciclovir requires cell-cell contact and occurs through gap junctions. 15, 16, 22 In contrast, the toxic metabolite of the CD/5-FC system, 5-FU, can freely diffuse over cell membranes from one cell to the other. 14, 20 LT12/Tk+N cells retain high levels of HSVtk activity in vivo and can be efficiently eliminated in vivo by ganciclovir treatment. However, late recurrences lacking HSVtk expression were observed in two out of three rats Our results provide no evidence for the escape of LT12/Tk+N-2 cells that retained HSVtk expression from the ganciclovir treatment, as has been demonstrated in a melanoma model. 23 HSVtk converts ganciclovir into a cell cycle-dependent toxin. It has been suggested that HSVtkexpressing cells temporarily out of cell cycle during ganciclovir treatment and HSVtk-expressing cells that are located in pharmacological sanctuaries may escape ganciclovir-induced cell death and that these residual cells may form tumors after discontinuation of the ganciclovir treatment. 23 Apparently in our rat AML model, all tkexpressing LT12 cells present in the s.c. tumors were killed during the 5-day ganciclovir treatment.
In this study, we did not extensively analyze the mechanism(s) causing the lack of HSVtk expression. Partial or complete deletion of the HSVtk gene has been described to be the underlying mechanism causing ganciclovir-resistance in ganciclovir-resistant colonies isolated from gastrointestinal tumor cell lines exposed to ganciclovir for 14 days. 24 In this study, all HSVtk loss mutants retained the HSVtk and Neo R genes in their genome. Cells in six of the seven aspirates lost not only the expression of HSVtk but concomitantly lost their acquired resistance to selection in G418-containing medium. Only cells derived from the aspirate from one late s.c. tumor retained their acquired resistance to G418, despite the loss of functional HSVtk expression. The cells in this tumor may have acquired a point mutation or frame shift in the HSVtk gene whereas the cells in the other six aspirates apparently lost expression of the whole bicistronic unit, possibly due to aberrant DNA methylation or deletions/mutations in the promotor region. Sequence analysis of the integrated copy of the pLTk+Neo⌬Mo vector in the genome, in combination with Northern blot analysis of the cells in the aspirates and treatment of the cells with the demethylating agent 5-azacytidine may provide information regarding the nature of the mechanism(s) underlying the loss of HSVtk gene expression.
In vivo elimination of suicide gene-expressing tumor cells have been shown to induce long-lasting tumor-specific immunity in various animal tumor models. [10] [11] [12] In our non-immunogenic rat AML model, prophylactic vaccination of tumor-free rats with live HSVtk expressing LT12 cells, followed by their in vivo elimination with ganciclovir, did not induce any protection against a simultaneous or subsequent challenge with parental LT12 cells. It is likely that the non-immunogenic nature of LT12 cells is a critical factor underlying the failure to elicit a LT12-specific immune response. Studies with cytokine expressing tumor cells showed that granulocyte-macrophage colony-stimulating factor (GM-CSF) has a stimulating effect on local antigen presentation by 'professional' antigen presenting cells. 25 Vaccination with lethally irradiated GM-CSF-producing LT12 cells did not induce an anti-leukemic immune response in our model (unpublished observations). Synergistic effects can be obtained by vaccination with tumor cells co-expressing the HSVtk suicide gene and a cytokine gene. 6, 26 Currently, we are investigating the possibility of inducing anti-LT12 immune responses by the in vivo elimination of LT12 cells that coexpress HSVtk and GM-CSF or IL-2.
The resistance to bystander cell lysis of LT12 cells and the absence of an effective local anti-tumor response at the site of vaccination with live LT12/Tk+N-2 cells allow HSVtk loss variants to survive the ganciclovir treatment and form late recurrent tumors. It is reasonable to assume that HSVtk loss variants also occur with low frequency in other tumor models. Presumably, in bystander cell lysis sensitive tumors, the HSVtk loss variants are completely eradicated during ganciclovir treatment by the 'bystander effect', thereby preventing the development of late tumors at the site of vaccination. A way to circumvent the problem with bystander cell lysis-resistant tumors, like LT12, in the HSVtk/ganciclovir system, might be to enhance the intercellular communication through gap junctions. Recently, it has been elegantly demonstrated that transfection with a gene encoding a gap junction forming protein, connexin 26, 37 or 43, can induce sensitivity to bystander cell lysis in cells that were previously resistant to bystander cell lysis in the HSVtk/ganciclovir system. 22, 27, 28 Thus, co-transduction of the HSVtk gene and one of the connexin genes into bystander cell lysis resistant tumor cells may prevent the development of late HSVtk loss tumors after vaccination with live cells followed with ganciclovir treatment. Alternatively, it may be beneficial to switch to another suicide gene/prodrug system, like CD/5-FC or PNP/MeP-dR, 29 that result in 'medium-mediated bystander effects' independent of cell to cell contact.
In conclusion, the in vivo occurrence of HSVtk loss variants escaping ganciclovir-induced elimination, suggests that some caution is appropriate when considering the use of live HSVtk gene-expressing tumor cell vaccines, especially with tumor cells that are not sensitive to bystander cell lysis such as AML cells.
Materials and methods
Animals
Inbred male Brown Norway (BN/Bi) rats, bred under specific pathogen-free conditions were purchased from the Harlan breeding facility, Zeist, The Netherlands and used at 12-16 weeks of age (body weight 200-250 g). Rats were housed in plastic cages in light-cycled rooms with acidified water and pelleted food ad libitum.
Tumor cells and retroviral vectors
The rat nonimmunogenic acute promyelocytic leukemic cell line LT12 is an in vitro growing cell line derived from the Brown Norway myeloid leukemia (BNML). It shows a reproducible growth pattern upon i.v. cellular transfer within the BN strain and has many characteristics in common with human acute promyelocytic leukemia. The BNML/LT12 rat model has been extensively described. 30 The pLTk+Neo⌬Mo retroviral vector contains a bicistronic unit, harboring the HSVtk gene and the Neo R selection marker gene separated by a short (36 bp) intercistronic sequence, under control of the promotor in the 5′ retroviral LTR. The LTR is a hybrid in which the MLV enhancer is replaced by the PyF101 enhancer that is active in both primitive and mature cells in vitro and in vivo. 31, 32 The pCD-2 retroviral vector (kindly provided by Dr CA Mullen, MDACC, Houston, TX, USA) contains the E. coli cytosine deaminase (CD) gene under control of the MMTV LTR promotor and the Neo R gene under control of the SV40 early promotor.
9 LT12 cells were transfected with either linearized pLTk+Neo⌬Mo or linearized pCD-2 vector by electroporation using the Gene Pulse Generator II (Biorad, Veenendaal, The Netherlands) according to the manufacturer's instructions. Three days after transfection, transfected cells were selected and cloned with G418 (400 g/ml Geneticin; Gibco, Breda, The Netherlands). Parental LT12 cells and transfectants of LT12 were cultured in RPMI 1640 medium (Gibco) supplemented with 10% fetal calf serum (FCS) (Gibco), 100 IU/ml penicillin and 100 g/ml streptomycin. Cells were cultured in a humidified atmosphere at 37°C and 5% CO 2 .
In vitro sensitivity to ganciclovir or 5-FC Parental LT12 cells or cloned pLTk+Neo⌬Mo-or pCD-2-transfected LT12 cells, designated LT12/Tk+N# or LT12/CD#, respectively, were cultured in quadruplicate in round-bottomed 96-well plates at a concentration of 5000 cells per well in the presence of various concentrations ganciclovir (Cymevene, a generous gift of Roche Nederland BV, Mijdrecht, The Netherlands) or 5-FC (Sigma, Amsterdam, The Netherlands). At day 2, 0.1 Ci 3 H-thymidine (Amersham, ′sHertogenbosch, The Netherlands) was added to the cultures and 18 h later cultures were harvested on to glass fiber filters and counted in a beta scintillation counter. The proliferative response of transfected-and parental LT12 cells in the presence of ganciclovir or 5-FC is presented as a percentage of the growth of these cells in medium without ganciclovir or 5-FC. The ID 50 value (the concentration of prodrug that inhibits proliferation by 50%) was calculated from these curves.
In vitro bystander cell lysis assay LT12/Tk+N-2 cells and parental LT12 cells (bystander cells) were co-cultured in quadruplicate in round-bottomed 96-well plates at various ratios to achieve a total cell number of 2 × 10 4 or 4 × 10 4 in the presence of 10 −6 m ganciclovir. Various numbers of both cell lines were also cultured separately in ganciclovir-containing medium. At day 2, 0.1 Ci 3 H-thymidine was added to the cultures, 18 h later cultures were harvested on to glass fiber filters and counted in a beta scintillation counter. The results obtained in the co-cultivations were compared with the calculated theoretical values in the absence of bystander cell lysis, which were obtained by the addition of the counts of the relevant numbers of the separate LT12 and LT12/Tk+N-2 cell cultures. Bystander cell lysis of LT12 cells by LT12/CD-1 cells exposed to 1.5 mm 5-fluorocytosine was measured in a similar way.
In vivo tumor cell growth and ganciclovir treatment To establish s.c. tumors, 5 × 10 5 cloned LT12/Tk+N-2 cells were injected s.c. in the right flank of BN rats. Rats were examined two to three times weekly until the tumor became palpable. Thereafter, the two largest perpendicular diameters were measured two to three times weekly using calipers and multiplied to obtain a measure for the tumor size. Rats were treated with i.p. injections of 50 mg/kg ganciclovir twice daily for 5 consecutive days from days 7 to 11, unless indicated otherwise. None of the rats showed any signs of toxicity at this dosage of prodrug treatment.
In the in vivo bystander experiments, various numbers of parental LT12 cells were co-injected with 5 × 10 
HSVtk and Neo
R PCR PCR to detect the HSVtk and Neo R genes was performed on DNA extracted from cultured cells obtained from aspirates. 10 6 Cells were pelleted and resuspended in 100 l PCR lysis buffer (0.5% Nonidet-40, 0.5% Tween-20 and 0.6 mg/ml proteinase K). Samples were digested at 55°C for 60 min, heated to 95°C for 10 min and then kept on ice. DNA (10 l, equivalent to 10 5 cells) was amplified in a 50 l reaction, containing 50 mm KCl, 10 mm TrisHCl (pH 9), 1.5 mm MgCl 2 , 0.2 mm dNTPs, 0.5 U Taq DNA polymerase (Promega, Leiden, The Netherlands) and 50 nm primers, using a Hybaid Omnigene thermal cycler (Hybaid, Teddington, UK). PCR conditions were 95°C for 5 min, followed by 30 cycles of 1 min 95°C, 1 min 55°C and 2 min 72°C and subsequently 5 min 72°C. The sequence of the PCR primers to detect the Neo R and HSVtk genes was: Neo R sense TACTCGGATGGAAG CCGGTC, Neo R antisense AGTCGATGAATCCAGAA AAG, HSV-Tk sense AACGGCGACCTGTATAACGT and HSVtk antisense TCAGTTAGCCTCCCCCATCT. PCR products were size-separated on 1.2% agarose gels containing ethidium bromide. The sensitivity of the PCRs was 10 −2 .
In vitro analysis of the frequency of tk-loss variants Various numbers of LT12/Tk+N-2 cells were seeded in soft agar in the presence of 10 −6 m ganciclovir in 6 cm diameter Petri dishes. The semi-solid culture medium was based on Dulbecco's modification of Eagle's medium 800 (Gibco) and contained 20% FCS, 2 mm l-glutamine, 1 mm sodium pyruvate, 50 m ␤-mercaptoethanol, 100 IU/ml penicillin and 100 g/ml streptomycin and 3 mg/ml agar (Bacto-agar, Difco Laboratories, Detroit, MI, USA). The plating efficiency of LT12/Tk+N-2 cells was determined by plating limiting numbers of LT12/Tk+N-2 cells in soft agar in the absence of ganciclovir and was found to be 60%. Colonies were counted approximately 10 days later. The frequency of tk-loss variants was calculated by dividing the number of colonies obtained per dish by the number of cells seeded per dish multiplied with the plating efficiency.
